Methods used in the present study, including thyroid function evaluation, have been described elsewhere [9 (link),16 (link),17 (link)]. A trained interviewer obtained information on clinical characteristics, such as history of thyroid disease, glucose-lowering medication use, and smoking and drinking habits. Body weight and height were measured using an automatic body composition analyzer (BF-220; Tanita, Tokyo, Japan). BMI (kg/m2) was calculated. Systolic blood pressure (SBP) was recorded at rest.
Fasting blood samples were collected. TSH, FT3, and FT4 levels were measured using standard procedures at the LSI Medience Corporation (Tokyo, Japan). Glycohemoglobin (HbA1c), triglyceride (TG), high-density lipoprotein cholesterol (HDLc), and creatinine levels were measured using standard procedures at SRL Inc. (Tokyo, Japan). GFR was estimated using an established method with three variables proposed by a working group of the Japanese Chronic Kidney Disease Initiative [18 (link)].
The threshold for SCH was set at TSH > 4.01 μIU/mL. CKD was defined as GFR < 60 mL/min/1.73 m2.
Fasting blood samples were collected. TSH, FT3, and FT4 levels were measured using standard procedures at the LSI Medience Corporation (Tokyo, Japan). Glycohemoglobin (HbA1c), triglyceride (TG), high-density lipoprotein cholesterol (HDLc), and creatinine levels were measured using standard procedures at SRL Inc. (Tokyo, Japan). GFR was estimated using an established method with three variables proposed by a working group of the Japanese Chronic Kidney Disease Initiative [18 (link)].
The threshold for SCH was set at TSH > 4.01 μIU/mL. CKD was defined as GFR < 60 mL/min/1.73 m2.
Free full text: Click here
